​

Amphastar Pharmaceuticals (AMPH) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

AMPH Stock Forecast

Amphastar Pharmaceuticals (AMPH) stock forecast, based on 11 Wall Street analysts, predicts a 12-month average price target of $32.00, with a high of $32.00 and a low of $32.00. This represents a 32.34% increase from the last price of $24.18.

$20 $29 $38 $47 $56 $65 High: $32 Avg: $32 Low: $32 Last Closed Price: $24.18

AMPH Stock Rating

Amphastar Pharmaceuticals stock's rating consensus is Buy, based on 11 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 6 Buy (54.55%), 5 Hold (45.45%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 11 0 5 6 Strong Sell Sell Hold Buy Strong Buy

AMPH Price Target Upside V Benchmarks

TypeNameUpside
StockAmphastar Pharmaceuticals32.34%
SectorHealthcare Stocks 15.45%
IndustrySpecialty & Generic Drug Manufacturers Stocks18.82%

Price Target Trends

1M3M12M
# Anlaysts--1
Avg Price Target--$32.00
Last Closing Price$24.18$24.18$24.18
Upside/Downside--32.34%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 25123--6
Sep, 25123--6
Aug, 25-24--6
Jul, 25-24--6
Jun, 25-24--6
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Mar 21, 2025David AmsellemPiper Sandler$32.00$28.2913.11%32.34%
Aug 08, 2024David AmsellemPiper Sandler$66.00$43.3152.39%172.95%
May 23, 2024David AmsellemPiper Sandler$71.00$43.3163.93%193.63%
Mar 12, 2022David AmsellemPiper Sandler$35.00$34.302.04%44.75%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Aug 12, 2025CitigroupBuyupgrade
Mar 21, 2025Piper SandlerNeutralNeutralhold
Feb 03, 2025Piper SandlerOverweightNeutraldowngrade
Aug 08, 2024Piper SandlerOverweightOverweighthold
Jun 27, 2024Piper SandlerOverweightOverweighthold
May 23, 2024Piper SandlerOverweightOverweighthold
Mar 12, 2022Piper SandlerOverweightOverweighthold

Financial Forecast

EPS Forecast

$0 $1 $2 $3 $4 $5 $6 $7 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$0.02$1.30$1.88$2.85$3.29----
Avg Forecast$0.59$1.31$1.64$3.36$3.89$4.09$4.80$5.79$4.44
High Forecast$0.63$1.39$1.69$3.65$4.15$4.36$5.55$6.05$4.64
Low Forecast$0.53$1.17$1.59$2.71$3.78$3.71$4.03$5.57$4.27
Surprise %-96.61%-0.76%14.63%-15.18%-15.42%----

Revenue Forecast

$300M $450M $600M $750M $900M $1B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$349.85M$437.77M$498.99M$644.39M$712.81M----
Avg Forecast$342.50M$428.50M$491.21M$639.60M$737.66M$796.71M$873.22M$971.50M$956.00M
High Forecast$357.22M$446.91M$501.79M$648.75M$740.49M$816.77M$873.29M$1.01B$989.29M
Low Forecast$314.06M$392.92M$479.89M$631.28M$733.29M$777.46M$873.14M$943.19M$928.14M
Surprise %2.15%2.16%1.58%0.75%-3.37%----

Net Income Forecast

$0 $70M $140M $210M $280M $350M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$1.10M$62.12M$91.39M$137.54M$159.52M----
Avg Forecast$31.42M$69.61M$86.92M$168.44M$210.13M$213.82M$254.00M$307.74M$235.32M
High Forecast$33.18M$73.50M$89.35M$193.37M$219.86M$231.12M$294.36M$320.49M$245.98M
Low Forecast$28.03M$62.09M$84.32M$143.51M$200.40M$196.53M$213.64M$295.00M$226.41M
Surprise %-96.51%-10.76%5.14%-18.34%-24.09%----

AMPH Forecast FAQ

Is Amphastar Pharmaceuticals stock a buy?

Amphastar Pharmaceuticals stock has a consensus rating of Buy, based on 11 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 6 Buy, 5 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Amphastar Pharmaceuticals is a favorable investment for most analysts.

What is Amphastar Pharmaceuticals's price target?

Amphastar Pharmaceuticals's price target, set by 11 Wall Street analysts, averages $32 over the next 12 months. The price target range spans from $32 at the low end to $32 at the high end, suggesting a potential 32.34% change from the previous closing price of $24.18.

How does Amphastar Pharmaceuticals stock forecast compare to its benchmarks?

Amphastar Pharmaceuticals's stock forecast shows a 32.34% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the specialty & generic drug manufacturers stocks industry (18.82%).

What is the breakdown of analyst ratings for Amphastar Pharmaceuticals over the past three months?

  • October 2025: 16.67% Strong Buy, 33.33% Buy, 50.00% Hold, 0% Sell, 0% Strong Sell.
  • September 2025: 16.67% Strong Buy, 33.33% Buy, 50.00% Hold, 0% Sell, 0% Strong Sell.
  • August 2025: 0% Strong Buy, 33.33% Buy, 66.67% Hold, 0% Sell, 0% Strong Sell.

What is Amphastar Pharmaceuticals’s EPS forecast?

Amphastar Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2025 is $4.09, marking a 24.32% increase from the reported $3.29 in 2024. Estimates for the following years are $4.8 in 2026, $5.79 in 2027, and $4.44 in 2028.

What is Amphastar Pharmaceuticals’s revenue forecast?

Amphastar Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2025 is $796.71M, reflecting a 11.77% increase from the reported $712.81M in 2024. The forecast for 2026 is $873.22M, followed by $971.5M for 2027, and $956M for 2028.

What is Amphastar Pharmaceuticals’s net income forecast?

Amphastar Pharmaceuticals's net income forecast for the fiscal year ending in December 2025 stands at $213.82M, representing an 34.04% increase from the reported $159.52M in 2024. Projections indicate $254M in 2026, $307.74M in 2027, and $235.32M in 2028.